Pfizer Inc (PFE)

33.64
NYSE : Health Care
Prev Close 33.74
Day Low/High 33.47 / 33.73
52 Wk Low/High 29.83 / 37.39
Avg Volume 23.79M
Exchange NYSE
Shares Outstanding 5.96B
Market Cap 200.93B
EPS 1.20
P/E Ratio 28.84
Div & Yield 1.28 (3.80%)

Latest News

Trump Executive Order Could Revive Allergan-Pfizer Merger

Trump Executive Order Could Revive Allergan-Pfizer Merger

The Trump administration's executive order on tax regulations could revive the defunct Allergan-Pfizer merger.

Pfizer Receives Positive CHMP Opinion For BESPONSA® (Inotuzumab Ozogamicin) For The Treatment Of Relapsed Or Refractory Acute Lymphoblastic Leukemia

Pfizer Receives Positive CHMP Opinion For BESPONSA® (Inotuzumab Ozogamicin) For The Treatment Of Relapsed Or Refractory Acute Lymphoblastic Leukemia

Pfizer Inc. (NYSE:PFE) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of BESPONSA ® ...

Global Distribution Of ATLAS Centers (Graphic: Business Wire)

Global Distribution Of ATLAS Centers (Graphic: Business Wire)

Pfizer Inc. today announced the launch of the company's Antimicrobial Testing Leadership and Surveillance (ATLAS) website, which is designed to provide physicians and the global health community with easy access to critical...

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

TherapeuticsMD Hormone Pill Faces Looming FDA Rejection and a Hostile Commercial Market

Postmenopausal women already have a broad menu of locally administered estrogen therapy products to treat vulvar and vaginal atrophy.

Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders

Pfizer Invites Public To Listen To Webcast Of April 27 Annual Meeting Of Shareholders

Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.

Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition

Johnson & Johnson Sees Little Impact In Key Area Despite Pfizer Competition

Pfizer launched a Remicade biosimilar in November.

Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick

Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick

A study of analyst recommendations at the major brokerages shows that Pfizer Inc is the #15 broker pick, on average, out of the 30 stocks making up the Dow Jones Industrial Average, according to ETF Channel. Within the broader S&P 500, when components were ranked in terms of analyst favorites, PFE claims the #253 spot.

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

Immunology Among Areas to Watch as Johnson & Johnson Gears Up to Report Results

JNJ's diabetes and oncology franchises will also be key when the New Brunswick, N.J.-based healthcare giant reports first-quarter numbers Tuesday morning.

Gilead, Pfizer, AbbVie Win From Lilly's Loss

Gilead, Pfizer, AbbVie Win From Lilly's Loss

The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Lilly and Incyte Fall After FDA Rejects Potential Blockbuster for Rheumatoid Arthritis

Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.

Mylan Falls on FDA Warning on Quality Control

Mylan Falls on FDA Warning on Quality Control

The EpiPen-maker has received a letter from the FDA about its manufacturing facility in Nashik, India.

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Jim Cramer -- Eli Lilly Is the New 'Darling' of Big Pharma

Eli Lilly has become the new go-to name in the pharmaceutical space, even over Johnson & Johnson, Cramer said.

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

Biotech Movers: OncoMed Tanks After Barrage of Bad News, Akorn Rises on Deal Talk

OncoMed Pharmaceuticals, Geron and Akorn were among the biotech stock movers in premarket trading on Monday.

21st Century Fox Enlists Law Firm to Investigate Bill O'Reilly Sexual Harassment Claims

21st Century Fox Enlists Law Firm to Investigate Bill O'Reilly Sexual Harassment Claims

The media giant has asked the same law firm that conducted an investigation into former Fox News CEO Roger Ailes, who was ousted in July.

Allergan and Celgene Are in Peak Health

Allergan and Celgene Are in Peak Health

These stocks should be part of a strong first-quarter earnings season.

Medivation Founder Takes Helm at Axovant, Shares Spike

Medivation Founder Takes Helm at Axovant, Shares Spike

David Hung will become Axovant's CEO after completing the $14 billion sale of Medivation to Pfizer.

Trump Team Financial Disclosures Reveal Millions in Stock Investments

Trump Team Financial Disclosures Reveal Millions in Stock Investments

Not only are many members of the Trump administration incredibly rich, but they are active investors as well.

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control

Washington needs to do more, Gottlieb says at his confirmation hearing.

Second-Quarter Picks and Pans

Second-Quarter Picks and Pans

Las Vegas Sands and Flexion are in, and the autos are out.

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

Why AbbVie Will be an Incredible Money-Making Machine in an Overvalued Stock Market

The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.

Mylan Has Been Pounded, but the Pain May be Far from Over

Mylan Has Been Pounded, but the Pain May be Far from Over

The maker of the EpiPen seems incapable of overcoming its troubles.

As Biotech Roars Back, Amgen Remains Dirt Cheap

As Biotech Roars Back, Amgen Remains Dirt Cheap

The biotechnology sector is enjoying robust recovery, driving Big Pharma shares to lofty levels. But this biotech stalwart is a great value play now.

Cramer: We Have Nothing to Distinguish the Stocks Right Now

Cramer: We Have Nothing to Distinguish the Stocks Right Now

We know that we are in the era when index managers are ascendant.

Dividend Stock Advisor Is Becoming Income Seeker

Subscribers to Dividend Stock Advisor will now receive Income Seeker, our newest premium product.

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

Busting the Shorts : Cramer's 'Mad Money' Recap (Thursday 3/30/17)

This month's resilience in the market has a lot to do with short squeezes in big tech names.

VBI Vaccines Emerges as Strong Biotech Stock

VBI Vaccines Emerges as Strong Biotech Stock

Armed with an arsenal of vaccines in its product pipeline, this small biotech company is ready to rocket.

Pfizer, Intrexon, Raytheon: 'Mad Money' Lightning Round

Pfizer, Intrexon, Raytheon: 'Mad Money' Lightning Round

Jim Cramer says Pfizer needs to do a deal and buy someone; and he thinks Raytheon is a terrific stock.